argenx announced the appointment of Karen Massey as Chief Executive Officer and Tim Van Hauwermeiren as Chairperson of the Board of Directors following the company’s Annual General Meeting of shareholders. The leadership transition marks what the company described as the next phase of growth for the immunology-focused biotechnology company.
Karen Massey joined argenx in March 2023 as Chief Operating Officer and succeeds Tim Van Hauwermeiren, who co-founded argenx and had served as Chief Executive Officer since 2008. Her appointment as CEO follows shareholder approval of her appointment as executive director of the Board of Directors.
Tim Van Hauwermeiren was appointed Chairperson of the Board of Directors following his election as a non-executive director during the General Meeting.
argenx said 90.9% of the company’s share capital was represented at the meeting and all agenda items received the required majority approval. Shareholders approved the company’s 2025 remuneration report, annual report and annual accounts, allocation of 2025 profits to retained earnings, and multiple Board of Directors appointments and reappointments.
Additional approvals included the reappointments of Ana Céspedes, Camilla Sylvest, and Pam Klein as non-executive directors, along with authorization to issue shares and grant rights to subscribe for shares representing up to 10% of the company’s outstanding share capital over an 18-month period.
argenx is a global immunology company focused on developing antibody-based medicines for severe autoimmune diseases. The company commercialized the first approved neonatal Fc receptor blocker and continues advancing treatments across multiple autoimmune disease indications.
KEY QUOTES:
“Karen has earned the full confidence of the Board of Directors and our shareholders. She is a proven leader who has played a central role in shaping argenx’s execution and long-term growth strategy. Karen leads with our responsibility to patients, the argenx culture, and a vision to continue to build our pipeline. I look forward to supporting Karen and the leadership team as argenx enters its next phase of growth.”
Tim Van Hauwermeiren, Chairperson Of The Board Of Directors, argenx
